tiprankstipranks
Structure Therapeutics Advances Obesity Treatment Candidate
Company Announcements

Structure Therapeutics Advances Obesity Treatment Candidate

Story Highlights
  • Structure Therapeutics selects ACCG-2671 as its lead candidate for obesity treatment.
  • Preclinical studies show ACCG-2671’s effectiveness and safety, with Phase 1 trials set for 2025.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Pick the best stocks and maximize your portfolio:

Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) has provided an announcement.

Structure Therapeutics Inc. has announced the selection of ACCG-2671, an oral small molecule amylin receptor agonist, as its lead candidate for obesity treatment. Preclinical studies show ACCG-2671’s effectiveness in weight loss with a favorable safety profile, supporting once-daily dosing. The company plans to initiate Phase 1 clinical trials by the end of 2025. This advancement positions Structure Therapeutics as a leader in developing amylin-based treatments that could significantly impact the treatment landscape for obesity and related conditions.

More about Structure Therapeutics, Inc. Sponsored ADR

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company focused on developing innovative oral small molecule therapeutics for chronic metabolic and cardiopulmonary conditions. The company uses its structure-based drug discovery platform to create a pipeline of GPCR-targeted small molecule compounds aimed at overcoming limitations of traditional biologic and peptide therapies, thereby increasing patient access worldwide.

YTD Price Performance: -23.95%

Average Trading Volume: 780,838

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $1.77B

See more insights into GPCR stock on TipRanks’ Stock Analysis page.

Related Articles
Michael MarcusJefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy’ Stocks
TheFlyStructure Therapeutics price target raised to $91 from $86 at JMP Securities
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App